EVOLVE Short DAPT with the SYNERGY BP Stent - YouTube
Primary Results of the EVOLVE Short DAPT Study | Circulation: Cardiovascular Interventions
EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com
Dual antiplatelet therapy after percutaneous coronary intervention in patients at high bleeding risk: A systematic review and meta-analysis | Han | Cardiology Journal
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
The Approach to the High-Risk of Bleeding patient - ppt download
Antiplatelet Therapy in High-Bleeding Risk Patients Undergoing PCI: Walking a Tightrope
A Personalized Approach to Antiplatelet Therapy - Cardiac Interventions Today
XIENCE Stent: Protecting Patients with Short DAPT Needs | Abbott
Evolving Concepts in Post-PCI Antiplatelets Therapy - Kartik Pandurang Jadhav, Pankaj V. Jariwala, 2020
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis | Nature Reviews Cardiology
Complex Coronary Cases - ppt download
EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent | tctmd.com
SYNERGY™ Programa Clínico - Ensayos cortos DAPT | Boston Scientific
Antiplatelet therapy after percutaneous coronary intervention | EuroIntervention
NUEVOS DATOS CLÍNICOS DE SYNERGY™ EN MÚLTIPLES ESCENARIOS CLÍNICOS. | SHCI - Sección de Hemodinámica y Cardiología Intervencionista de la SEC (Sociedad Española de Cardiología)
NUEVOS DATOS CLÍNICOS DE SYNERGY™ EN MÚLTIPLES ESCENARIOS CLÍNICOS. | SHCI - Sección de Hemodinámica y Cardiología Intervencionista de la SEC (Sociedad Española de Cardiología)
SYNERGY™ Programa Clínico - Ensayos cortos DAPT | Boston Scientific
Julie Soldo (@SoldoJulie) / X
Dual antiplatelet therapy duration after percutaneous coronary intervention using drug eluting stents in high bleeding risk pati
The Evolving SYNERGY Programs: EVOLVE-Short DAPT Updates | tctmd.com
Boston Scientific reports positive trial data for Synergy stent
ISCHEMIC RISK MATTERS - RISK STRATIFICATION IN HIGH BLEEDING RISK (HBR) PATIENTS IMPLANTED WITH THE SYNERGY STENT: A POST-HOC ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal of the American College
Dual antiplatelet therapy after percutaneous coronary intervention in patients at high bleeding risk: A systematic review and meta-analysis | Han | Cardiology Journal
JCM | Free Full-Text | Evolution of Coronary Stent Platforms: A Brief Overview of Currently Used Drug-Eluting Stents
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation | JACC: Cardiovascular Interventions
EVOLVE Short DAPT: A Single Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated with a Bioabsorbable Polymer- Ba
Primary Results of the EVOLVE Short DAPT Study | Circulation: Cardiovascular Interventions
Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention - ScienceDirect
